• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MKI67、TPR 和 TCHH 突变鉴定为 II/III 期错配修复缺陷结直肠癌患者的预后生物标志物。

Identification of MKI67, TPR , and TCHH Mutations as Prognostic Biomarkers for Patients With Defective Mismatch Repair Colon Cancer Stage II/III.

机构信息

Department of Colorectal Surgery, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.

Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.

出版信息

Dis Colon Rectum. 2023 Nov 1;66(11):1481-1491. doi: 10.1097/DCR.0000000000002734. Epub 2023 Aug 29.

DOI:10.1097/DCR.0000000000002734
PMID:37643197
Abstract

BACKGROUND

Stage II/III disease is the most predominant form of colorectal cancer, accounting for approximately 70% of cases. Furthermore, approximately 15% to 20% of patients with stage II/III disease have deficient mismatch repair or microsatellite instability-high colorectal cancer. However, there are no identified significant prognostic biomarkers for this disease.

OBJECTIVE

To identify prognostic markers for patients with deficient mismatch repair/microsatellite instability-high colon cancer stage II/III.

DESIGN

Retrospective study design.

SETTING

The study was conducted at a high-volume colorectal center, the Cancer Hospital, Chinese Academy of Medical Sciences.

PATIENTS

Patients diagnosed with stage II/III deficient mismatch repair/microsatellite instability-high colon cancer who underwent curative surgery at the Cancer Hospital at the Chinese Academy of Medical Sciences between July 2015 and November 2018 were included.

MAIN OUTCOME MEASURES

The primary outcome measure was the influence of differentially mutated genes on progression-free survival.

RESULTS

The retrospective deficient mismatch repair/microsatellite instability-high cohort involved 32 patients and The Cancer Genome Atlas-microsatellite instability-high cohort involved 45 patients. Patients with deficient mismatch repair/microsatellite instability-high colon cancer had higher mutational frequencies of MKI67 , TPR , and TCHH than patients with microsatellite stable colon cancer. MKI67 , TPR , TCHH , and gene combination were significantly correlated with prognosis. The biomarker mutation-type colon cancer group had a higher risk of recurrence or death than did the wild-type group. Moreover, biomarker mutation-type tumors had more mutations in the DNA damage repair pathway and tumor mutational burden than did biomarker wild-type tumors.

LIMITATIONS

This study was limited by its retrospective nature.

CONCLUSIONS

MKI67 , TPR , and TCHH may serve as potential diagnostic and prognostic biomarkers for deficient mismatch repair/microsatellite instability-high colon cancer stage II/III.

IDENTIFICACIN DE MUTACIONES MKI, TPR Y TCHH COMO BIOMARCADORES PRONSTICOS PARA PACIENTES CON CNCER DE COLON EN ETAPA II/III CON DEFICIENCIA EN LA REPARACION DE ERRORES DE EMPAREJAMIENTO: ANTECEDENTES:La enfermedad en estadio II/III es la forma más predominante de cáncer colorrectal y representa aproximadamente el 70% de los casos. Además, aproximadamente entre el 15% y el 20% de los pacientes con enfermedad en estadio II/III tienen reparación deficiente de errores de emparejamiento o inestabilidad de microsatélital alta. Sin embargo, no se han identificado biomarcadores pronósticos significativos para esta enfermedad.OBJETIVO:Este estudio tuvo como objetivo identificar marcadores pronósticos para pacientes con cáncer de colon con reparación deficiente de errores de emparejamiento/inestabilidad microsatelital alta en estadio II/III.DISEÑO:Diseño de estudio retrospectivo.ESCENARIO:El estudio se realizó en un centro colorrectal de alto volumen, el Hospital del Cáncer de la Academia China de Ciencias Médicas.PACIENTES:Pacientes diagnosticados con cáncer de colon en estadio II/III con reparación deficiente de errores de emparejamiento o inestabilidad de microsatélital alta que se sometieron a cirugía curativa en el Hospital del Cáncer de la Academia China de Ciencias Médicas entre julio de 2015 y noviembre de 2018.MEDIDAS DE RESULTADO PRINCIPALES:La medida de resultado primaria fue la influencia de los genes con mutaciones diferenciales en la supervivencia libre de progresión.RESULTADOS:La cohorte retrospectiva de reparación deficiente de errores de emparejamiento o inestabilidad de microsatélital alta y la cohorte de inestabilidad microsatelital alta del Atlas del Genoma del Cáncer involucraron a 32 y 45 pacientes, respectivamente. Los pacientes con de reparación deficiente de errores de emparejamiento/inestabilidad microsatélital alta tuvieron frecuencias mutacionales más altas de MKI67 , TPR y TCHH que los pacientes estables de microsatélites. MKI67 , TPR , TCHH , y la combinación de genes se correlacionaron significativamente con el pronóstico. El grupo de cáncer de colon de tipo mutación de biomarcador tenía un mayor riesgo de recurrencia o muerte que el grupo de mutación salvaje. Además, los tumores de tipo mutación de biomarcadores tenían más mutaciones en la vía de reparación del daño del ADN y la carga mutacional del tumor que los tumores de tipo salvaje de biomarcadores.LIMITACIONES:Este estudio estuvo limitado por su naturaleza retrospectiva.CONCLUSIONES:MKI67 , TPR , y TCHH pueden servir como posibles biomarcadores de diagnóstico y pronóstico para cáncer de colon en estadio II/III con reparación deficiente de errores de emparejamiento/inestabilidad microsatélital alta. (Traducción-Dr. Jorge Silva Velazco ).

摘要

背景

II/III 期疾病是最主要的结直肠癌形式,约占 70%的病例。此外,约 15%至 20%的 II/III 期疾病患者存在错配修复缺陷或微卫星不稳定高结直肠癌。然而,目前还没有确定针对这种疾病的显著预后生物标志物。

目的

确定错配修复缺陷/微卫星不稳定高 II/III 期结直肠癌患者的预后标志物。

设计

回顾性研究设计。

地点

该研究在一家高容量的结直肠中心——中国医学科学院肿瘤医院进行。

患者

2015 年 7 月至 2018 年 11 月期间,在中国医学科学院肿瘤医院接受根治性手术治疗的 II/III 期错配修复缺陷/微卫星不稳定高结直肠癌患者。

主要观察指标

主要观察指标是差异突变基因对无进展生存期的影响。

结果

回顾性错配修复缺陷/微卫星不稳定高队列纳入 32 例患者,癌症基因组图谱微卫星不稳定高队列纳入 45 例患者。与微卫星稳定结直肠癌患者相比,错配修复缺陷/微卫星不稳定高结直肠癌患者的 MKI67、TPR 和 TCHH 突变频率更高。MKI67、TPR、TCHH 和基因组合与预后显著相关。标志物突变型结肠癌组的复发或死亡风险高于野生型组。此外,标志物突变型肿瘤的 DNA 损伤修复途径和肿瘤突变负荷比标志物野生型肿瘤更多。

局限性

本研究受到其回顾性的限制。

结论

MKI67、TPR 和 TCHH 可能是错配修复缺陷/微卫星不稳定高 II/III 期结直肠癌的潜在诊断和预后生物标志物。

相似文献

1
Identification of MKI67, TPR , and TCHH Mutations as Prognostic Biomarkers for Patients With Defective Mismatch Repair Colon Cancer Stage II/III.MKI67、TPR 和 TCHH 突变鉴定为 II/III 期错配修复缺陷结直肠癌患者的预后生物标志物。
Dis Colon Rectum. 2023 Nov 1;66(11):1481-1491. doi: 10.1097/DCR.0000000000002734. Epub 2023 Aug 29.
2
Clinicopathological Characteristics and Outcomes of Colorectal Cancer With Heterogenous Staining of Mismatch Repair Protein.错配修复蛋白异质性染色的结直肠癌的临床病理特征及预后
Dis Colon Rectum. 2025 Jan 1;68(1):48-59. doi: 10.1097/DCR.0000000000003527. Epub 2024 Sep 27.
3
Characteristics of Mismatch Repair-Deficient Colon Cancer in Relation to Mismatch Repair Protein Loss, Hypermethylation Silencing, and Constitutional and Biallelic Somatic Mismatch Repair Gene Pathogenic Variants.错配修复缺陷型结直肠癌的特征与错配修复蛋白缺失、高甲基化沉默以及胚系和双等位基因体细胞错配修复基因致病性变异有关。
Dis Colon Rectum. 2023 Apr 1;66(4):549-558. doi: 10.1097/DCR.0000000000002452. Epub 2022 Jun 20.
4
Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.新辅助免疫检查点抑制改善错配修复缺陷的T4bM0期结直肠癌的器官保留:一项回顾性观察研究
Dis Colon Rectum. 2023 Oct 1;66(10):e996-e1005. doi: 10.1097/DCR.0000000000002466. Epub 2023 Mar 29.
5
Prognostic Impact of Mucinous Adenocarcinoma in Stage II and III Colon Cancer.黏液腺癌对Ⅱ期和Ⅲ期结肠癌的预后影响
Dis Colon Rectum. 2023 Nov 1;66(11):1473-1480. doi: 10.1097/DCR.0000000000002733. Epub 2023 Oct 11.
6
Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR/MSI-H Status.错配修复缺陷/微卫星高度不稳定型局部晚期和可切除转移性结直肠癌患者的新辅助免疫治疗。
Dis Colon Rectum. 2024 Nov 1;67(11):1413-1422. doi: 10.1097/DCR.0000000000003290. Epub 2024 Sep 11.
7
Is High-Grade Tumor Budding an Independent Prognostic Factor in Stage II Colon Cancer?高级别肿瘤芽生是II期结肠癌的独立预后因素吗?
Dis Colon Rectum. 2023 Aug 1;66(8):e801-e808. doi: 10.1097/DCR.0000000000002345. Epub 2022 Apr 5.
8
Multiple High-Risk Features for Stage II Colon Carcinoma Portends Worse Survival Than Stage III Disease.II期结肠癌的多种高危特征预示着比III期疾病更差的生存率。
Dis Colon Rectum. 2023 Aug 1;66(8):1076-1084. doi: 10.1097/DCR.0000000000002425. Epub 2022 Feb 28.
9
Prognostic Value of Venous Invasion Detected by Elastin Stain May Surpass Lymph Node Status in Colon Cancer.弹性纤维染色检测静脉侵犯对结肠癌的预后价值可能超过淋巴结状态。
Dis Colon Rectum. 2021 Aug 1;64(8):955-963. doi: 10.1097/DCR.0000000000001968.
10
Prognostic Characteristics of Patients With Colorectal Cancer Who Have Benign Mesenteric Lymph Node Enlargement: A Multi-institutional Cohort Study.患有良性肠系膜淋巴结肿大的结直肠癌患者的预后特征:一项多机构队列研究。
Dis Colon Rectum. 2022 Jun 1;65(6):804-816. doi: 10.1097/DCR.0000000000002085. Epub 2022 May 3.

引用本文的文献

1
Single-cell technology reveals the crosstalk between tumor cells and immune cells: driving immune signal transduction and inflammation-mediated cardiac dysfunction in the tumor microenvironment of colorectal cancer.单细胞技术揭示肿瘤细胞与免疫细胞间的串扰:驱动免疫信号转导及炎症介导的结直肠癌肿瘤微环境中的心脏功能障碍
Front Immunol. 2025 Aug 6;16:1637144. doi: 10.3389/fimmu.2025.1637144. eCollection 2025.
2
GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer.GNGT1是胃癌中一种潜在的预后和免疫生物标志物。
Sci Rep. 2025 Jul 1;15(1):21149. doi: 10.1038/s41598-025-08297-4.
3
Integrated Network Analysis Decipher ZNF384-Related miR-20b-5p and miR-424-5p in Colon Adenocarcinoma.
整合网络分析解析结肠癌中与ZNF384相关的miR-20b-5p和miR-424-5p
Cancer Rep (Hoboken). 2025 May;8(5):e70233. doi: 10.1002/cnr2.70233.
4
Development of a nomogram predicting perineural invasion risk and assessment of the prognostic value of perineural invasion in colon cancer: a population study based on the Surveillance, Epidemiology, and End Results database.预测结肠癌神经周围侵犯风险的列线图的开发及神经周围侵犯预后价值的评估:一项基于监测、流行病学和最终结果数据库的人群研究
Transl Cancer Res. 2025 Jan 31;14(1):141-158. doi: 10.21037/tcr-24-1030. Epub 2025 Jan 23.
5
Deep Learning-Enabled Integration of Histology and Transcriptomics for Tissue Spatial Profile Analysis.基于深度学习的组织学与转录组学整合用于组织空间特征分析
Research (Wash D C). 2025 Jan 17;8:0568. doi: 10.34133/research.0568. eCollection 2025.
6
TCHH as a Novel Prognostic Biomarker for Patients with Gastric Cancer by Bioinformatics Analysis.通过生物信息学分析,TCHH作为胃癌患者一种新的预后生物标志物
Clin Exp Gastroenterol. 2024 Feb 26;17:61-74. doi: 10.2147/CEG.S451676. eCollection 2024.